Deborah Mulford
| Title | Assistant Professor of Clinical |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Medicine |
|---|
| Address | University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester NY 14642
|
|---|
|
|
|
| Title | Assistant Professor of Clinical |
|---|
| Institution | University of Rochester Medical Center |
|---|
| Department | Cancer Center |
|---|
|
|
|---|
|
| 1986 |
-
| 1990 | Tidmarsh Scholarship for Piano | | 1988 |
-
| 1990 | Eta Kappa Nu and Tau Beta Pi Engineering Honor Societies | | 1989 |
-
| 1990 | Stearns Prize | | 1990 |
|
| Warner King Prize | | 1991 |
|
| U.S. and European Patent-Photographic Apparatus for an Optical Instrument | | 1996 |
|
| International Cancer Fellowship | University of Rochester Medical School | | 2003 |
-
| 2005 | Lauri Strauss Leukemia Foundation Endowed Fellowship | Lauri Strauss Leukemia Foundation | | 2003 |
-
| 2005 | Mortimer J. Lacher Fellowship Award | | 2004 |
-
| 2006 | NIH Clinical Loan Repayment Program | NIH |
-
Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr 15; 118(8):2138-47.
-
Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest. 2011 Aug; 29(7):439-50.
-
Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011 Jul 21; 118(3):523-8.
-
Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010 Nov 1; 16(21):5303-11.
-
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.
-
Laughlin TS, Becker MW, Liesveld JL, Mulford DA, Abboud CN, Brown P, Rothberg PG. Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia. J Mol Diagn. 2008 Jul; 10(4):338-45.
-
Mulford D. Antibody therapy for acute myeloid leukemia. Semin Hematol. 2008 Apr; 45(2):104-9.
-
Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005 Jan; 46 Suppl 1:199S-204S.
-
Mulford DA, Jurcic JG. Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Ther. 2004 Jan; 4(1):95-105.
|
Mulford's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
